Follow-On Biologics’ Development Time Requires Picking Brand Winners Early
Executive Summary
Developing follow-on biologics will require sponsors to make much better predictions about the future marketplace than are currently necessary for ANDAs, according to Insmed VP-Regulatory Affairs Glen Kelley